Biotech company Pharming Group NV today announces that it has granted Sobi additional rights to market Ruconest in Spain, Portugal, Andorra and Greece. Sobi thereby has the exclusive distribution rights in all European Union countries, Iceland, Norway and Switzerland.
Sobi was also recently granted rights to market Ruconest in the Balkans (Albania, Bosnia and Herzegovina, Croatia, Kosovo, Macedonia, Montenegro, Moldavia), North Africa (Algeria, Morocco, Syria, Tunisia) and the Middle East (Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Oman, Quatar, Saudi Arabia, UAE, Yemen).